Predictors for efficacy of combination therapy with a nucleos(t)ide analogue and interferon for chronic hepatitis B
Hong Li(Union Hospital), Dongliang Yang, Cheng‐Yuan Peng(China Medical University), Xin Zheng(Wuhan Union Hospital), Zhihong Weng(North China Electric Power University), Hua Wang(Huazhong University of Science and Technology), Jia Liu(Shanghai Public Health Clinical Center)
Journal of Huazhong University of Science and Technology [Medical Sciences]
August 1, 2017
Cited by 9
Related Papers
Mitotic and G <sub>2</sub> Checkpoint Control: Regulation of 14-3-3 Protein Binding by Phosphorylation of Cdc25C on Serine-216
|Science|1997|1.3k
SIRveNIB: Selective Internal Radiation Therapy Versus Sorafenib in Asia-Pacific Patients With Hepatocellular Carcinoma
|Journal of Clinical Oncology|2018|653
Elbasvir–Grazoprevir to Treat Hepatitis C Virus Infection in Persons Receiving Opioid Agonist Therapy
|Annals of Internal Medicine|2016|364
All-oral daclatasvir plus asunaprevir for hepatitis C virus genotype 1b: a multinational, phase 3, multicohort study
|The Lancet|2014|343
Cyclin A/CDK2 binds directly to E2F-1 and inhibits the DNA-binding activity of E2F-1/DP-1 by phosphorylation.
|Molecular and Cellular Biology|1994|284